IL15 and neoplasm: Preclinical studies have shown that IL-15 enhances CTL responses in murine tumor models and the administration of IL-15 in combination with anti-PD-L1and anti-CTLA-4 antibodies showed greater cytolytic and effector functions on the CD8+ T cells of metastatic tumor-bearing animals [81,82,83,84,85].